Tonon R, Simioni M, Lazzarin P, Bedendo A, Todesco S
Minerva Med. 1984 May 12;75(20):1189-92.
Twenty patients with inflammatory (15) or degenerative (5) joint disorders had been treated with 450 mg/day of proglumetacin during 35 +/- 18 days. Articular symptoms showed a definite and continued improvement, particularly evident during the initial 15 days of treatment on both painful and inflammatory components. The final physician's evaluation rated 75% of results as excellent or good, versus 15% of poor (3 patients, one of whom already refractory to diclofenac). The tolerance was defined as excellent to good in 90% of patients: one (5%) was dropped out upon the onset of sweating and palpitation, already observed with other drugs. Overall, only one case each of heartburn, anorexia and diarrhoea were considered as possibly related to the treatment. Laboratory tests did not show any variation that could be attributed to the drug. Proglumetacin therefore, by force of its efficacy and safety, appears to be particularly suited as a first-choice drug for the management of both inflammatory and degenerative joint disorders.
20例患有炎性（15例）或退行性（5例）关节疾病的患者在35±18天内接受了每日450毫克丙谷美辛的治疗。关节症状显示出明确且持续的改善，在治疗的最初15天内，疼痛和炎症成分方面尤为明显。最终医生评估结果显示，75%为优或良，15%为差（3例患者，其中1例对双氯芬酸已耐药）。90%的患者耐受性为优或良：1例（5%）在出现出汗和心悸时退出研究，其他药物也曾出现过这种情况。总体而言，仅各有1例烧心、厌食和腹泻被认为可能与治疗有关。实验室检查未显示任何可归因于该药物的变化。因此，鉴于其疗效和安全性，丙谷美辛似乎特别适合作为治疗炎性和退行性关节疾病的首选药物。
